Maternal Lateral Tilt and Cardiac Output in Caesarean Section
Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Nov 21, 2021
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
The primary outcome was to test if CO decreases significantly after LUD removal in patients under SA for CD. This is a prospective observational study.
Data were gathered from pregnant patients who, in addition to standard monitoring, underwent perioperative non-invasive hemodynamic monitoring by ClearSight system on the Edwards Lifesciences HemoSphere platform (Edwards Lifesciences, Irvine, CA).
The parameters were recorded at 20 seconds-intervals. The investigators considered 4 timepoints. T1 were the baseline values recorded for 5 minutes, after initial stabilization of parameters, wit...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • pregnant patients at term (36th to 40th week of gestation) scheduled for elective caesarean section under spinal anesthesia.
- Exclusion Criteria:
- • age \<18 years
- • American Society of Anesthesiologists score \>3
- • cardiac arrhythmias or aortic regurgitation
- • pregnancy-induced hypertension
- • pre-eclampsia
- • body mass index (BMI) \> 35 kg/m2
- • foetal complications
- • coagulation disorders or contraindication to neuraxial block
- • emergency surgery
- • preoperative infection
- • patient's refusal
About Fondazione Policlinico Universitario Agostino Gemelli Irccs
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is a leading research and healthcare institution based in Rome, Italy, renowned for its commitment to advancing medical science and improving patient care. As a prominent academic medical center affiliated with the Catholic University of the Sacred Heart, it integrates clinical practice, education, and research, fostering innovation in various fields of medicine. The foundation conducts a wide range of clinical trials aimed at developing new therapies and enhancing treatment protocols, with a focus on translational research that bridges the gap between laboratory discoveries and patient care. Its multidisciplinary approach and dedication to high ethical standards position it as a key player in the landscape of clinical research and healthcare improvement in Italy and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, , Italy
Patients applied
Trial Officials
Gaetano A Draisci, MD
Study Director
IRCCS Fondazione Policlinico Universitario Agostino Gemelli
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials